Active substance
Hydroxychloroquine
- SFDA 9
- US FDA 17
- Health Canada 6
- US price lines 4
- NHS prices 2
- WHO EML 1
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ARTHOSAVE 200 mg tablet | 200 mg | Tablet · Oral use | 100 Bottle | SAR 127.00 | Generic · Prescription | APOTEX | Valid |
| Hydroxychloroquine SAJA | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 71.80 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| Hydroxychloroquine Sulfate | 200 mg | Tablet · Oral use | 100 Blister | SAR 109.10 | Generic · Prescription | Qomel Co | Valid |
| PLAQUENIL 200MG TAB | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 84.45 | NCE · Prescription | Sanofi-aventis Ireland Limited | Valid |
| Quenfil | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 65.45 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| Vasrasti | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 76.05 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| PLAQUENIL 200MG TAB | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 93.80 | NCE · Prescription | AVENTIS PHARMA LIMITED | Withdrawn by MAH · Not Marketed |
| PLAQUENIL 200MG TAB | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 117.25 | NCE · Prescription | SANOFI-SYNTHLABO | Withdrawn by MAH · Not Marketed |
| RESOCHIN AMP 250MG-5ML | 50 mg/ml | Injection · Intravenous use | 5 Ampoule | SAR 18.65 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANTIPHOSPHOLIPID SYNDROME; GRAFT VERSUS HOST DISEASE; JUVENILE IDIOPATHIC ARTHRITIS (JIA); LICHEN PLANUS; MYOSITIS; RHEUMATOID ARITHRITIS; SARCOIDOSIS; SJOGREN'S SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PLAQUENIL | 200MG | tablet · oral | ADVANZ PHARMA | Prescription | 18 Apr 1955 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | TEVA PHARMS | Prescription | 30 Sep 1994 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | SANDOZ | Prescription | 30 Nov 1995 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | CREEKWOOD PHARMS | Prescription | 27 Jan 1996 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | AUROBINDO PHARMA USA | Prescription | 29 May 1998 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | IPCA LABS LTD | Prescription | 14 Jun 2007 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | ZYDUS PHARMS USA INC | Prescription | 21 Sep 2007 |
| HYDROXYCHLOROQUINE SULFATE | 200MG; 100MG; 300MG; 400MG | tablet · oral | APPCO | Prescription | 1 May 2018 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | ALKALOIDA ZRT | Prescription | 8 May 2018 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | AMNEAL PHARMS CO | Prescription | 15 May 2018 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | CHARTWELL RX | Prescription | 6 Jul 2018 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | LAURUS | Prescription | 15 Jan 2019 |
| HYDROXYCHLOROQUINE SULFATE | 200MG; 100MG; 300MG; 400MG | tablet · oral | ACCORD HLTHCARE | Prescription | 7 Apr 2020 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | SENORES PHARMS | Prescription | 14 May 2020 |
| SOVUNA | 200MG; 300MG | tablet · oral | NOVITIUM PHARMA | Prescription | 14 Jan 2022 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | WATSON LABS | Discontinued | 30 Nov 1995 |
| HYDROXYCHLOROQUINE SULFATE | 200MG | tablet · oral | HIKMA PHARMS | Discontinued | 15 Aug 2007 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-HYDROXYQUINE | 02246691 | 200 MG | TABLET · ORAL | APOTEX INC |
| HYDROXYCHLOROQUINE | 02519348 | 200 MG | TABLET · ORAL | SANIS HEALTH INC |
| JAMP HYDROXYCHLOROQUINE SULFATE | 02491427 | 200 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MINT-HYDROXYCHLOROQUINE | 02424991 | 200 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| NRA-HYDROXYCHLOROQUINE | 02511886 | 200 MG | TABLET · ORAL | NORA PHARMA INC |
| PLAQUENIL | 02017709 | 200 MG | TABLET · ORAL | SANOFI-AVENTIS CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | HYDROXYCHLOROQUINE 100 MG TAB | $0.18906 | per EA | 23 Sep 2026 |
| US NADAC | HYDROXYCHLOROQUINE 200 MG TAB | $0.14901 | per EA | 23 Sep 2026 |
| US NADAC | HYDROXYCHLOROQUINE 300 MG TAB | $0.53021 | per EA | 23 Sep 2026 |
| US NADAC | HYDROXYCHLOROQUINE 400 MG TAB | $0.66981 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Hydroxychloroquine 200mg tablets | £3.93 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Hydroxychloroquine 300mg tablets | £25.64 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 29.2. Disease-modifying anti-rheumatic drugs (DMARDs) · complementary
Systemic lupus erythematosus; Cutaneous lupus erythematosus of unspecified type
Oral > Solid: 200 mg (as sulfate)
Safety signals and safety-related labeling changes
- US FDA 10 Oct 2024 SOVUNA — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Dec 2023 PLAQUENIL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Jul 2023 HYDROXYCHLOROQUINE SULFATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 26 Nov 2020 PRAC signal: Psychiatric disorders
Action for MAH: update of the product information: Yes - EMA PRAC 3 Sep 2020 PRAC signal: Psychiatric disorders
Action for MAH: update of the product information: No - EMA PRAC 11 Jun 2020 PRAC signal: Psychiatric disorders
Action for MAH: update of the product information: No - EMA PRAC 5 Sep 2013 PRAC signal: Hypoglycaemia
Action for MAH: update of the product information: Yes
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.